bioMerieux acquires PML Microbiologicals

Published: 9-Dec-2008

bioMerieux, a leader in in vitro diagnostics, has acquired PML Microbiologicals, a North American provider of culture media and microbiological products for clinical and industrial applications, for US$29.6m.


Founded in 1969, PML has 205 employees with 2007 sales of US$24m. The company specialises in reagents, including prepared culture media (PPM) for sterility testing and environmental monitoring, as well as control organisms, which are complementary to bioMerieux's offering.

The acquisition will enable bioMerieux to become a leading provider in the US of microbiology testing systems for pharmaceutical companies. In addition, bioMerieux will enter the North American clinical PPM market, becoming a leading PPM provider for clinical applications in Canada.

PML's sites in Portland and Toronto will join bioMerieux's worldwide network of culture media production centres.

bioMerieux purchased 100% of PML Microbiologicals' shares from the privately held Pelican Life Sciences Group, based in San Diego.

  • Companies:
  • bioMerieux
See more

You may also like

Regulatory

UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul

Read more
The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue

Trending Articles

  1. AdvanceTEC drives cleanroom innovation & growth with acquisition by Equans Leveraging scale, global reach, technology, prefabrication & modularisation
  2. Medicinal cannabis production with GMP-compliant cleanroom solutions Controlled environments are supporting quality, safety and regulatory compliance in cannabis manufacturing
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    President Trump signs order for “regulatory relief” for domestic pharmaceutical manufacturers The US President has signed an executive order to direct the FDA to review current regulatory procedures, such as by reducing inspection frequency
  4. Pharmaceutical carbon reduction expert EECO2 achieves B Corp status A relatively unique certification in the cleanroom design industry, EECO2 has been determined to meet the necessary high standards of social and environmental performance, transparency, and accountability for B Corporation status
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Integrating “high-voltage leak detection” into automated visual inspection Leoni Ransmann and Jan Sende from Syntegon Technology talk about visual inspection of product containers like ampoules, which has been the industry standard for decades, and compare it to modern methods being emphasised in documents like the new EU GMP Annex 1

Upcoming event

Cleanzone Middle East

September 18-19 2025 | Conference | Conrad Dubai, United Arab Emirates See all

You may also like

Regulatory

UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul

The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue
Analysis

bioMérieux and JMI partner to fight antimicrobial resistance

The two firms have announced a six year partnership to undertake collaborative projects evaluating the performance and increasing potential of rapid and innovative microbiology diagnostics as important tools in the battle against AMR
Cleaning

bioMérieux launches assay for simultaneous Salmonella and Listeria detection

France-based bioMérieux has introduced GENE-UP ENVIROPRO that simultaneously detects both Salmonella and Listeria through a single enriched sample with PCR confirmation
Manufacturing

Recombinant Factor C assay to aid demand for LAL endotoxin testing

Kevin Williams from bioMerieux discusses the recombinant Factor C assay that has been developed to help alleviate the pressures of a growing demand for the Limulus amoebocyte lysate assay
Finance

bioMerieux acquires molecular testing company

The acquisition of the molecular testing platform, Veriflow, will compliment bioMérieux’s Gene-up system

bioMérieux 9.6% growth in 2016

Growth 9.6% at constant exchange rates, €2,103 million in sales
Analysis

bioMérieux launches automated diagnostic solution for microbial detection

EviSight Compact provides reliable results for increased product safety and reduces costs for pharmaceutical companies
Subscribe now